Genes Involved in Angiogenesis and mTOR Are Frequently Found Mutated in Asian Patients with Pancreatic Neuroendocrine Tumors. Abstract #1315

Introduction: There are limited data and inconsistent findings of genetic alteration in pancreatic neuroendocrine tumors (pNET).
Aim(s): We sequenced genes known to be associated with pNET and analyzed their impact on clinical outcomes in a Taiwanese cohort.
Materials and methods: Tissue samples from 40 Taiwanese patients with sporadic pNETs were sequenced using a customized sequencing panel that analyzed 43 genes known to be potentially associated with pNET. Genetic mutations and clinical outcomes were analyzed for potential association.
Conference: 13th Annual ENETS conference (2016)
Category: Basic Science - Genetics, epigenetics, miRNAs
Presenting Author: MD Chen Ming-Huang

To read results and conclusion, please login ...

Further abstracts you may be interested in

#62 Genome-wide DNA methylation profiling of pancreatic neuroendocrine tumors identifies distinct methylation profiles and differentially methylated gene promoter regions associated with low, medium and high grade tumors
Introduction: Integration of genetics and epigenetics has emerged as a powerful approach to studying cellular differentiation (Mikkelsen et al, 2009) and tumorigenesis (Shen et al, 2007). The study of DNA methylation is of particular importance in cancer, as causal involvement has been demonstrated and it is the most stable of all epigenetic modifications, making it a desirable marker for both early detection and treatment of tumors. Hypermethylation of CpG sites in gene promoter regions leads to decreased gene expression; if such a gene is a tumor suppressor, this leads to carcinogenesis. To date, there have been no studies of genome-wide DNA methylation profiling of NETs. This study sets out to determine the DNA methylation profiles of low, intermediate and high grade pancreatic NET liver metastases with the intention of identifying dysregulated biological pathways in the development of these tumors. A protocol for the analysis formalin-fixed paraffin embedded tissue (FFPE) has also been developed in order to study these tumors in significant numbers following this pilot study.
Conference: 7th Annual ENETS Conference (2010)
Category: Basic
Presenting Author: Dr Christina Thirlwell
#100 Mammalian target of rapamycin (mTOR) expression analysis and therapeutic approach in lung and gastroenteropancreatic poorly differentiated endocrine carcinoma (PDEC)
Introduction: PDEC clinically include gastroenteropancreatic PDEC, small cell lung cancer (SCLC) and large cell neuroendocrine carcinoma (LCNEC). These tumors are clinically similar and aggressive and they are usually treated with platinum compounds. mTOR signalling pathway has emerged as a promising target for well-differentiated endocrine carcinoma therapy. Because of varying behavior, PDEC are usually excluded from clinical trials employing the mTOR inhibitor RAD001.
Conference: 7th Annual ENETS Conference (2010)
Category: Basic
Presenting Author: Emilio Bajetta
#151 Rationale for combining mTOR with other targeted agents in the treatment of neuroendocrine tumors
Introduction: Advanced neuroendocrine tumors (NETs) are aggressive and incurable with standard treatment. Many cellular targets are being evaluated in this patient population, including mammalian target of rapamycin (mTOR), a kinase that is the central regulator of several signaling pathways related to cell growth, angiogenesis, and bioenergetics. Because mTOR serves as a neoplastic switch activated by many cancer-related mutations, mTOR inhibition may have broad efficacy across tumor types, including NETs. Somatostatin analogs (SSAs) have long been used to treat carcinoid symptoms in NET patients. The SSA octreotide long-acting release (LAR) demonstrated significant antitumor effects against advanced midgut NETs in the phase III PROMID study.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Kjell Öberg
Authors: Öberg K, Yao J C, ...
#437 mTOR Expression in Primary Pancreatic Neuroendocrine Tumors and their Metastases
Introduction: The mammalian target of rapamycin (mTOR), an important regulator of cell proliferation and invasion, is activated in pancreatic neuroendocrine tumors (PNETs). Information on detailed expression of mTOR in locally advanced or metastatic PNET is poorly described.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Prof Vera Delektorskaya
Authors: Kozlov N, Pavlovskaya A, ...
#592 Expression of PTEN and mTOR in Pancreatic Neuroendocrine Tumors and Their Clinical Significance
Introduction: mTOR is currently under investigation as a potential target for anticancer therapy. Loss of PTEN, the negative regulators of the PI3K-Akt-mTOR pathway, have been associated with cancer.
Conference: 10th Annual ENETS Conference (2013)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: Xu Han
Authors: Han X, Ji Y, Zhao J, Xu X, ...